This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle Estrogen Receptor-α36 Mediates EGFR-SGK1 Signaling-Related Erk Activation in Gastric Cancer by Yibo ZhangYibo Zhang SciProfiles Scilit Preprints.org Google Scholar 1,2,†, Hongyan...
Drs Lee and Saxena on the Role of PD-L1 as a Biomarker of Osimertinib Response in EGFR-Mutated NSCLC Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of...
BackgroundOsimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). However Abstract Background: Osimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell...
Open AccessCase Report A Case of Primary EGFR T790M Mutation in Treatment-Naïve Advanced NSCLC: Clinical and Molecular Implications by George DimitrovGeorge Dimitrov SciProfiles Scilit Preprints.org Google Scholar 1,2,*, Elitsa KraevskaElitsa Kraevska SciProfiles Scilit Preprints.org Google Scholar 2,3, Vladislav NankovVladislav Nankov...
Abstract Pancreatic cancer is the third leading cause of cancer-related death, with a 5-year survival rate of only 10%. Preclinical studies remain essential for identifying novel therapeutic strategies, discovering biomarkers, and deepening the understanding of disease biology. The most frequent...
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessReview The Occupational and Environmental Respiratory Exposome as a Potential Modulator of Adaptive Resistance to EGFR and ALK Inhibitors in Non-Small Cell...
SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17...
